StocksFundsScreenerSectorsWatchlists
RPTX

RPTX - Repare Therapeutics Inc Stock Price, Fair Value and News

3.51USD-0.14 (-3.84%)Market Closed

Market Summary

RPTX
USD3.51-0.14
Market Closed
-3.84%

RPTX Stock Price

View Fullscreen

RPTX RSI Chart

RPTX Valuation

Market Cap

148.1M

Price/Earnings (Trailing)

-1.58

Price/Sales (Trailing)

2.9

EV/EBITDA

-0.37

Price/Free Cashflow

-1.15

RPTX Price/Sales (Trailing)

RPTX Profitability

EBT Margin

-201.79%

Return on Equity

-44.23%

Return on Assets

-36.94%

Free Cashflow Yield

-87.19%

RPTX Fundamentals

RPTX Revenue

Revenue (TTM)

51.1M

Rev. Growth (Yr)

-28.31%

Rev. Growth (Qtr)

504.31%

RPTX Earnings

Earnings (TTM)

-93.8M

Earnings Growth (Yr)

11.46%

Earnings Growth (Qtr)

-48.47%

Breaking Down RPTX Revenue

Last 7 days

-13.1%

Last 30 days

-33.7%

Last 90 days

-45.2%

Trailing 12 Months

-61.3%

How does RPTX drawdown profile look like?

RPTX Financial Health

Current Ratio

6.24

RPTX Investor Care

Shares Dilution (1Y)

0.25%

Diluted EPS (TTM)

-2.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023111.7M91.5M71.3M51.1M
20227.8M49.2M90.5M131.8M
20212.0M3.9M5.7M7.6M
2020000135.0K

Tracking the Latest Insider Buys and Sells of Repare Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
zinda michael
sold
-1,910
4.66
-410
evp, chief scientific officer
Apr 01, 2024
forte steve
sold
-3,637
4.61
-789
evp, chief financial officer
Apr 01, 2024
segal lloyd mitchell
sold
-11,533
4.63
-2,491
president and ceo
Apr 01, 2024
koehler maria
sold
-1,398
4.66
-300
evp, chief medical officer
Mar 28, 2024
forte steve
sold
-3,811
4.62
-825
evp, chief financial officer
Mar 28, 2024
zinda michael
sold
-2,088
4.64
-450
evp, chief scientific officer
Mar 28, 2024
segal lloyd mitchell
sold
-12,243
4.62
-2,650
president and ceo
Mar 28, 2024
koehler maria
sold
-2,320
4.64
-500
evp, chief medical officer
Mar 27, 2024
zinda michael
sold
-2,079
4.62
-450
evp, chief scientific officer
Mar 27, 2024
forte steve
sold
-3,811
4.62
-825
evp, chief financial officer

1–10 of 50

Which funds bought or sold RPTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
reduced
-16.52
-449,338
457,411
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
reduced
-10.06
-354,817
422,494
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
sold off
-100
-206,000
-
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
524
774,000
1,054,000
0.09%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
207,576
207,576
-%
Feb 15, 2024
Blue Owl Capital Holdings LP
new
-
22,794,200
22,794,200
5.45%
Feb 15, 2024
BARCLAYS PLC
reduced
-86.93
-45,000
4,000
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-94.46
-148,696
5,154
-%
Feb 14, 2024
Redmile Group, LLC
reduced
-10.64
-13,362,900
15,685,900
0.56%
Feb 14, 2024
HighVista Strategies LLC
unchanged
-
-789,527
1,205,760
0.44%

1–10 of 44

Are Funds Buying or Selling RPTX?

Are funds buying RPTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RPTX
No. of Funds

Unveiling Repare Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
blue owl capital holdings lp
7.41%
3,122,499
SC 13G
Feb 14, 2024
deep track capital, lp
7.10%
2,992,731
SC 13G/A
Feb 14, 2024
redmile group, llc
5.1%
2,148,748
SC 13G/A
Jan 29, 2024
ark investment management llc
6.70%
2,821,560
SC 13G/A
Nov 17, 2023
biotechnology value fund l p
12.6%
5,309,432
SC 13D/A
Nov 03, 2023
biotechnology value fund l p
11.1%
4,662,402
SC 13D
Feb 14, 2023
biotechnology value fund l p
10.6%
4,443,423
SC 13G/A
Feb 14, 2023
redmile group, llc
6.4%
2,684,396
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
0.1%
26,894
SC 13G/A
Feb 14, 2023
deep track capital, lp
6.50%
2,727,606
SC 13G/A

Recent SEC filings of Repare Therapeutics Inc

View All Filings
Date Filed Form Type Document
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Mar 27, 2024
144
Notice of Insider Sale Intent
Mar 27, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 26, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Repare Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
39.7B
6.8B
0.01% -33.89%
-8.42
5.79
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.6B
1.8B
-1.06% -27.57%
-42.25
10.17
76.23% 61.08%
17.3B
2.4B
9.12% -7.56%
103
7.14
15.42% 18.43%
12.0B
3.7B
-8.48% -28.30%
20.07
3.25
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.27% -36.41%
-11.74
15.65
425.83% 18.94%
4.5B
-
-6.46% 74.90%
-6.94
60.35
54.84% -34.79%
3.2B
270.6M
-9.62% -0.34%
-13.52
11.95
440.80% -27.84%
3.0B
240.7M
-15.06% -21.14%
-10.03
12.36
-1.03% -92.09%
2.8B
726.4M
-8.60% -6.11%
-45.41
3.83
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-4.17% -12.95%
25.42
4.56
85.90% -14.05%
576.6M
983.7M
-22.12% -55.02%
-1.06
0.59
-50.36% 17.16%
448.6M
881.7K
-2.13% 345.78%
-10.06
466.16
-77.61% -5.33%
256.8M
4.9M
2.33% 7.75%
-1.9
52.78
-54.97% 51.72%
6.7M
2.1M
82.86% 81.13%
-0.25
2.14
-13.45% 66.37%

Repare Therapeutics Inc News

Latest updates
Yahoo Movies Canada12 Apr 202411:20 pm

Repare Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue504.3%13,047,0002,159,00030,249,00024,223,50018,198,000112,545,00056,476,500408,0006,877,000278,000279,000166,000-
Operating Expenses8.2%43,914,00040,577,00042,507,00040,359,00037,830,00039,146,00039,413,00035,237,00035,611,00031,957,00026,946,00021,746,00017,212,000
  S&GA Expenses9.9%8,648,0007,868,0008,719,0008,529,0007,939,0007,904,0007,938,0008,779,0007,639,0006,596,0006,741,0005,237,0004,795,000
  R&D Expenses7.8%35,266,00032,709,00033,788,00031,830,00029,891,00031,242,00031,475,00026,458,00027,972,00025,361,00020,205,00016,509,00012,417,000
EBITDA Margin-Infinity%-1.92-0.25-0.06-0.08-0.26-2.67-15.28-14.06-16.59-19.99-31.23-397
Income Taxes101.2%190,000-16,299,0003,110,0003,616,00015,028,00054,00033,00032,000-412,000-708,000-421,000-137,000-1,554,000
Earnings Before Taxes20.9%-27,840,000-35,178,000-8,836,000-31,325,000-16,630,00075,515,000-38,060,000-34,725,000-28,702,000-31,600,000-26,730,000-21,554,000-16,817,000
EBT Margin-56.5%-2.02-1.290.20-0.09-0.11-0.29-2.71-15.53-14.29-16.87-20.36-31.85-
Net Income-48.5%-28,030,000-18,879,000-11,946,000-34,941,000-31,658,00075,461,000-38,093,000-34,757,000-28,290,000-30,892,000-26,309,000-21,417,000-15,263,000
Net Income Margin-34.3%-1.83-1.37-0.03-0.26-0.22-0.28-2.69-15.33-14.07-16.37-19.84-31.10-
Free Cashflow13.1%-28,554,000-32,870,000-35,411,000-32,261,000-27,917,00087,892,000-29,762,000-30,493,000-20,903,000-33,097,000-18,487,000-14,999,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets-11.3%254286302336364409308337369296321339357370382103
  Current Assets-11.4%24427529232635439129031935128030932834736137799.00
    Cash Equivalents3.6%11110711612116015527630533426129431232634837095.00
  Net PPE-10.7%4.005.005.005.004.005.005.005.006.004.004.004.004.003.002.002.00
Liabilities-21.2%42.0053.0056.0085.0085.0010383.0078.0080.0077.0076.0071.0070.0069.0068.0013.00
  Current Liabilities-20.2%39.0049.0053.0081.0079.0062.0039.0034.0035.0023.0023.0012.0011.0010.0010.004.00
Shareholder's Equity-9.1%212233245251280306226259288218245268287301314-
  Retained Earnings-9.2%-333-305-286-274-239-207-283-245-210-181-151-124-103-88.09-74.34-49.94
  Additional Paid-In Capital11.3%62.0056.0049.0043.0037.0032.0027.0023.0018.0014.0011.008.006.005.004.004.00
Shares Outstanding0.1%42.0042.0042.0042.0042.0042.0042.0042.0042.0037.0037.0037.00----
Float---383---455---812---704-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations14.3%-28,156-32,870-34,346-31,786-29,63788,158-28,193-30,006-20,738-32,773-18,058-14,227-12,947-20,10436,684-9,717---
  Share Based Compensation-0.3%6,3596,3776,2656,0625,1385,0534,7454,7553,8963,6933,1832,0571,006871389271---
Cashflow From Investing30.1%31,87924,49828,350-6,68634,058-208,930-1,309403-398-389-117-772-9,247-473-13.00-30.00---
Cashflow From Financing-63.0%10528440.0041316526920524194,562363449183289-1,695249,026222---

RPTX Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue:  
Collaboration agreements$ 51,133$ 131,830
Operating expenses:  
Research and development, net of tax credits133,593119,066
General and administrative33,76432,560
Total operating expenses167,357151,626
Loss from operations(116,224)(19,796)
Other income (expense), net  
Realized and unrealized gain (loss) on foreign exchange(170)308
Interest income13,3345,631
Other expense, net(119)(43)
Total other income, net13,0455,896
Loss before income taxes(103,179)(13,900)
Income tax benefit (expense)9,383(15,147)
Net loss(93,796)(29,047)
Unrealized gain (loss) on available-for-sale marketable securities456(428)
Total other comprehensive income (loss)456(428)
Comprehensive loss$ (93,340)$ (29,475)
Net loss per share attributable to common shareholders--basic$ (2.23)$ (0.69)
Net loss per share attributable to common shareholders--diluted$ (2.23)$ (0.69)
Weighted-average common shares outstanding-basic42,093,29341,922,042
Weighted-average common shares outstanding-diluted42,093,29341,922,042

RPTX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 111,268$ 159,521
Marketable securities112,359184,420
Income tax receivable10,8130
Other current receivables4,4994,323
Prepaid expenses4,7495,715
Total current assets243,688353,979
Property and equipment, net4,2154,228
Operating lease right-of-use assets3,3265,371
Income tax receivable2,2760
Other assets396497
TOTAL ASSETS253,901364,075
Current liabilities:  
Accounts payable2,400461
Accrued expenses and other current liabilities24,05721,645
Operating lease liabilities, current portion2,4002,171
Deferred revenue, current portion10,22253,102
Income tax payable01,240
Total current liabilities39,07978,619
Operating lease liabilities, net of current portion1,0103,257
Deferred revenue, net of current portion1,7302,682
TOTAL LIABILITIES41,81984,558
Commitments and Contingencies
SHAREHOLDERS' EQUITY:  
Preferred shares, no par value per share; unlimited shares authorized as of December 31, 2023 and December 31, 2022, respectively; 0 shares issued and outstanding as of December 31, 2023, and December 31, 2022, respectively00
Common shares, no par value per share; unlimited shares authorized as of December 31, 2023 and December 31, 2022; 42,176,041 and 42,036,193 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively483,350482,032
Additional paid-in capital61,81337,226
Accumulated other comprehensive loss28(428)
Accumulated deficit(333,109)(239,313)
TOTAL SHAREHOLDERS' EQUITY212,082279,517
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$ 253,901$ 364,075
RPTX
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.
 CEO
 WEBSITEreparerx.com
 INDUSTRYBiotechnology
 EMPLOYEES180

Repare Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Repare Therapeutics Inc? What does RPTX stand for in stocks?

RPTX is the stock ticker symbol of Repare Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Repare Therapeutics Inc (RPTX)?

As of Mon Apr 15 2024, market cap of Repare Therapeutics Inc is 148.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RPTX stock?

You can check RPTX's fair value in chart for subscribers.

What is the fair value of RPTX stock?

You can check RPTX's fair value in chart for subscribers. The fair value of Repare Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Repare Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RPTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Repare Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RPTX is over valued or under valued. Whether Repare Therapeutics Inc is cheap or expensive depends on the assumptions which impact Repare Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPTX.

What is Repare Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, RPTX's PE ratio (Price to Earnings) is -1.58 and Price to Sales (PS) ratio is 2.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RPTX PE ratio will change depending on the future growth rate expectations of investors.